253 related articles for article (PubMed ID: 31596028)
21. Development of gene editing strategies for human β-globin (HBB) gene mutations.
Kalkan BM; Kala EY; Yuce M; Karadag Alpaslan M; Kocabas F
Gene; 2020 Apr; 734():144398. PubMed ID: 31987908
[TBL] [Abstract][Full Text] [Related]
22. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
24. Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system.
Trakarnsanga K; Thongsin N; Metheetrairut C; Tipgomut C; Poldee S; Wattanapanitch M
Sci Rep; 2022 Sep; 12(1):15551. PubMed ID: 36114353
[TBL] [Abstract][Full Text] [Related]
25. The molecular characterization of Beta globin gene in thalassemia patients reveals rare and a novel mutations in Pakistani population.
Yasmeen H; Toma S; Killeen N; Hasnain S; Foroni L
Eur J Med Genet; 2016 Aug; 59(8):355-62. PubMed ID: 27263053
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
27. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.
Cromer MK; Camarena J; Martin RM; Lesch BJ; Vakulskas CA; Bode NM; Kurgan G; Collingwood MA; Rettig GR; Behlke MA; Lemgart VT; Zhang Y; Goyal A; Zhao F; Ponce E; Srifa W; Bak RO; Uchida N; Majeti R; Sheehan VA; Tisdale JF; Dever DP; Porteus MH
Nat Med; 2021 Apr; 27(4):677-687. PubMed ID: 33737751
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome Analyses of β-Thalassemia -28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs).
Li J; Zhou Z; Sun HX; Ouyang W; Dong G; Liu T; Ge L; Zhang X; Liu C; Gu Y
Front Genet; 2020; 11():577053. PubMed ID: 33193694
[TBL] [Abstract][Full Text] [Related]
30. Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment.
Ali G; Tariq MA; Shahid K; Ahmad FJ; Akram J
Gene Ther; 2021 Feb; 28(1-2):6-15. PubMed ID: 32355226
[TBL] [Abstract][Full Text] [Related]
31. Amelioration of beta654-thalassemia in mouse model with the knockdown of aberrantly spliced beta-globin mRNA.
Xie S; Li W; Ren Z; Zhang J; Guo X; Wang S; Huang S; Zeng F; Zeng YT
J Genet Genomics; 2008 Oct; 35(10):595-601. PubMed ID: 18937916
[TBL] [Abstract][Full Text] [Related]
32. Prime Editor 3 Mediated Beta-Thalassemia Mutations of the
Zhang H; Zhou Q; Chen H; Lu D
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563395
[TBL] [Abstract][Full Text] [Related]
33. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
Mettananda S; Fisher CA; Hay D; Badat M; Quek L; Clark K; Hublitz P; Downes D; Kerry J; Gosden M; Telenius J; Sloane-Stanley JA; Faustino P; Coelho A; Doondeea J; Usukhbayar B; Sopp P; Sharpe JA; Hughes JR; Vyas P; Gibbons RJ; Higgs DR
Nat Commun; 2017 Sep; 8(1):424. PubMed ID: 28871148
[TBL] [Abstract][Full Text] [Related]
34. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
[TBL] [Abstract][Full Text] [Related]
35. Hb Knossos (HBB: c.82G > T), β-globin CD 5 (-CT) (HBB: c.17_18delCT) and δ-globin CD 59 (-a) (HBD: c.179delA) mutations in a Syrian patient with β-thalassemia intermedia.
Moassas F; Nweder MS; Murad H
BMC Pediatr; 2019 Feb; 19(1):61. PubMed ID: 30777047
[TBL] [Abstract][Full Text] [Related]
36. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
37. Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells.
Patsali P; Turchiano G; Papasavva P; Romito M; Loucari CC; Stephanou C; Christou S; Sitarou M; Mussolino C; Cornu TI; Antoniou MN; Lederer CW; Cathomen T; Kleanthous M
Haematologica; 2019 Nov; 104(11):e497-e501. PubMed ID: 31004018
[No Abstract] [Full Text] [Related]
38. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies.
Wienert B; Martyn GE; Funnell APW; Quinlan KGR; Crossley M
Trends Genet; 2018 Dec; 34(12):927-940. PubMed ID: 30287096
[TBL] [Abstract][Full Text] [Related]
39. Genetic disruption of the KLF1 gene to overexpress the γ-globin gene using the CRISPR/Cas9 system.
Shariati L; Khanahmad H; Salehi M; Hejazi Z; Rahimmanesh I; Tabatabaiefar MA; Modarressi MH
J Gene Med; 2016 Oct; 18(10):294-301. PubMed ID: 27668420
[TBL] [Abstract][Full Text] [Related]
40. Association between Different Polymorphic Markers and β-Thalassemia Intermedia in Central Iran.
Sajadpour Z; Amini-Farsani Z; Motovali-Bashi M; Yadollahi M; Khosravi-Farsani N
Hemoglobin; 2020 Jan; 44(1):27-30. PubMed ID: 31899996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
